Global CGT Landscape: Q2 2025 Report Highlights
- SSCTR Exco
- Oct 15
- 1 min read
Published by ASGCT & Citeline
The ASGCT Q2 2025 report shows sustained CGT momentum with new approvals in gene and mRNA therapies, steady deal activity, and rising oncology focus. M&A volume increased sharply, led by major pharma consolidations in advanced therapies.
👉 Read the full report: ASGCT Gene, Cell, & RNA Therapy Landscape Report Q2 2025
Disclaimer
Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link. SSCTR does not provide medical advice, and the views expressed are for educational purposes only.
Comments